Tonix Pharmaceuticals
TNXP
19 hedge funds and large institutions have $2.99M invested in Tonix Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 9 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
0% less ownership
Funds ownership: 0% → 0% (-0%)
17% less funds holding
Funds holding: 23 → 19 (-4)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
73% less capital invested
Capital invested by funds: $11.1M → $2.99M (-$8.14M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.52M |
| 2 |
Millennium Management
New York
|
+$319K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$294K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$245K |
| 5 |
Two Sigma Investments
New York
|
+$245K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
M
Murchinson
Toronto,
Ontario, Canada
|
-$5.05M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$712K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$123K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$80K |
| 5 |
Squarepoint
New York
|
-$75K |
TNXP Hedge Fund Activity: Q3 2022 in Review
19 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q3 2022, worth a combined $2.99M — down 73% from $11.1M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of TNXP and 5 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.52M. The largest seller was Murchinson, exiting entirely with an estimated $5.05M sold.
- 19 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q3 2022, down from 23 in Q2 2022.
- Funds reported $2.99M of Tonix Pharmaceuticals stock for Q3 2022, down 73% quarter-over-quarter.
- 5 funds opened new Tonix Pharmaceuticals positions in Q3 2022 and 9 closed out, a net change of -4 holders.
- The largest Tonix Pharmaceuticals buyer in Q3 2022 was Renaissance Technologies, an estimated $1.52M added.
- The largest Tonix Pharmaceuticals seller in Q3 2022 was Murchinson, an estimated $5.05M sold.
Based on aggregated 13F filings for Q3 2022.